Orchestra BioMed has surpassed its target of 316 patients in the pivotal BACKBEAT trial. Full enrollment positions the company to submit primary endpoint data in late 2027, supporting Medtronic's future FDA applications for AVIM Therapy.
Orchestra BioMed has surpassed its target of 316 patients in the pivotal BACKBEAT trial. Full enrollment positions the company to submit primary endpoint data in late 2027, supporting Medtronic's future FDA applications for AVIM Therapy.